Literature DB >> 6100602

Cardiac and haemodynamic effects of enalapril.

F M Fouad, R C Tarazi, E L Bravo.   

Abstract

The haemodynamic effects of enalapril were evaluated by sequential radionuclide studies in 10 patients followed for three to seven months. The pattern of response was remarkably similar to that of angiotensin antagonists and other oral converting enzyme inhibitors; it consisted of a reduction in peripheral resistance, minimal blood volume changes and no significant increase in either cardiac output or heart rate. The haemodynamic and neurohumoral responses to upright tilt remained normal, despite the lack of supine tachycardia in response to peripheral vasodilation. The pattern of response suggests that the haemodynamic effects of enalapril resulted from interference with angiotensin II (AII) generation rather than from a direct drug effect. Serial echocardiographic studies showed a significant regression in left ventricular (LV) hypertrophy in six out of seven hypertensive patients followed sequentially for three to seven months. Ventricular performance was well preserved despite the reduction in ventricular mass, as indicated by maintenance of the normal relationship of LV fractional shortening (% Sh) to LV end-systolic stress.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6100602

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  10 in total

Review 1.  Role of ACE inhibitors in hypertension with left ventricular hypertrophy.

Authors:  A M Richards; M G Nicholls; I G Crozier
Journal:  Br Heart J       Date:  1994-09

2.  Comparison of enalapril and propranolol in essential hypertension.

Authors:  B A van Schaik; G G Geyskes; N Kettner; P Boer; E J Mees
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 3.  Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  P A Todd; R C Heel
Journal:  Drugs       Date:  1986-03       Impact factor: 9.546

4.  Left ventricular mass changes with nicardipine therapy in essential hypertension.

Authors:  P Gosse; P Lacroix; R Roudaut; M Dallocchio
Journal:  Cardiovasc Drugs Ther       Date:  1989-08       Impact factor: 3.727

5.  Characterization of cardiac angiotensin converting enzyme (ACE) and in vivo inhibition following oral quinapril to rats.

Authors:  B Fabris; H Yamada; R Cubela; B Jackson; F A Mendelsohn; C I Johnston
Journal:  Br J Pharmacol       Date:  1990-07       Impact factor: 8.739

Review 6.  An overview of the clinical pharmacology of enalapril.

Authors:  R O Davies; H J Gomez; J D Irvin; J F Walker
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

7.  Effects of long term treatment with pinacidil and nifedipine on left ventricular anatomy and function in patients with mild to moderate systemic hypertension.

Authors:  F Steensgaard-Hansen; J E Carlsen
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 8.  Enalapril: a review of human pharmacology.

Authors:  H J Gomez; V J Cirillo; J D Irvin
Journal:  Drugs       Date:  1985       Impact factor: 9.546

Review 9.  Haemodynamic responses to specific renin-angiotensin inhibitors in hypertension and congestive heart failure. A review.

Authors:  R J Cody
Journal:  Drugs       Date:  1984-08       Impact factor: 9.546

Review 10.  Comparative cardiovascular effects of drugs used for hypertension.

Authors:  M Burnier; B Waeber; J Nussberger; H R Brunner
Journal:  Drugs       Date:  1990       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.